Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Mahonia Aquifolium Root Bark
Brand Name
Psoriaflora
Generic Name
Mahonia Aquifolium Root Bark
Active Ingredient
Mahonia Aquifolium Root BarkCategory
Non-Standardized Plant Allergenic Extract [EPC]
Variants
2
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 2 [hp_X]/28g | CREAM | TOPICAL | 68466-2005 |
| 2 [hp_X]/28g | CREAM | TOPICAL | 53499-1990 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Psoriaflora, you must consult a qualified healthcare professional.
Detailed information about Psoriaflora
Mahonia Aquifolium Root Bark is a non-standardized plant allergenic extract and adrenergic agonist used in clinical immunology and homeopathic medicine for skin and inflammatory conditions.
Dosage for Mahonia Aquifolium Root Bark is highly dependent on the formulation and the condition being treated.
Mahonia Aquifolium Root Bark is not routinely recommended for pediatric use in conventional medicine due to a lack of robust safety data, particularly regarding the alkaloid berberine.
There are no specific dosage adjustment guidelines for Mahonia Aquifolium Root Bark in patients with renal impairment. However, since a portion of the alkaloids is excreted renally, caution is advised. Patients with Stage 3 or higher chronic kidney disease (CKD) should consult their nephrologist before use.
Because the liver is the primary site of alkaloid metabolism, patients with hepatic insufficiency (e.g., cirrhosis or hepatitis) may experience increased systemic exposure. Lower doses or increased monitoring for toxicity is recommended.
Geriatric patients should start at the lowest end of the dosing range. Factors such as reduced skin barrier function (for topical use) and decreased renal/hepatic clearance (for oral use) must be considered.
If you miss a dose, take it or apply it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up.
Signs of oral overdose may include severe gastrointestinal distress (nausea, vomiting, diarrhea), dizziness, lethargy, or signs of adrenergic overstimulation (tachycardia, palpitations). Topical overdose is rare but may manifest as severe skin irritation or contact dermatitis. In case of suspected ingestion of large quantities, contact a Poison Control Center (1-800-222-1222) or seek emergency medical attention immediately.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
When used topically, the most common side effects involve localized skin reactions. These are usually mild and self-limiting:
Mahonia Aquifolium Root Bark is a potent pharmacological agent. It is not 'just a plant extract'—it contains alkaloids that significantly interact with human physiology. Patients with a history of severe allergies to members of the Berberidaceae family (such as Barberry or Goldenseal) should avoid this product.
No FDA black box warnings for Mahonia Aquifolium Root Bark.
Mahonia Aquifolium Root Bark must NEVER be used in the following circumstances:
FDA Category: Not Assigned (Botanical). However, clinical consensus strongly advises against use during pregnancy. Berberine, the primary active constituent, is known to be a 'uterine stimulant' in animal models, which could potentially lead to preterm labor or miscarriage. Furthermore, berberine's ability to displace bilirubin from albumin poses a significant risk of kernicterus (permanent brain damage) to the developing fetus if significant systemic absorption occurs. There are no controlled data in human pregnancy, and use is considered high-risk.
It is unknown if the alkaloids from Mahonia Aquifolium Root Bark pass into breast milk in significant quantities. However, because of the extreme sensitivity of neonates to bilirubin displacement, breastfeeding while taking oral Mahonia Aquifolium is contraindicated. Topical use on small areas of the body (away from the breast) may be less risky but should still be discussed with a pediatrician.
Mahonia Aquifolium Root Bark acts through several molecular pathways. Its primary alkaloid, berberine, is a quaternary ammonium salt from the protoberberine group of isoquinoline alkaloids. It functions as an alpha-1 adrenergic agonist, stimulating smooth muscle and vascular tone. It also shows activity as a beta-adrenergic agonist, which can influence intracellular cAMP levels. In skin cells, it inhibits the enzyme lipoxygenase, which reduces the production of leukotrienes—key mediators of inflammation in psoriasis. Additionally, it has been shown to downregulate the expression of keratin 6 and keratin 16, proteins that are overexpressed in psoriatic skin.
The pharmacodynamic effect of topical Mahonia is localized; it reduces skin cell proliferation and inflammation without significant systemic immunosuppression. When taken orally, its effects on blood glucose are mediated by the activation of AMP-activated protein kinase (AMPK), which increases insulin sensitivity and reduces hepatic glucose production. The onset of action for topical psoriasis treatment is typically 4 to 8 weeks, with maximum benefit seen at 12 weeks.
Common questions about Psoriaflora
Mahonia Aquifolium Root Bark is primarily used in clinical settings as an allergenic extract for diagnosing and treating plant-specific allergies. In dermatology, it is a well-regarded treatment for mild-to-moderate plaque psoriasis and eczema due to its ability to slow down skin cell overgrowth. It is also found in various homeopathic remedies intended to support liver function and skin health. Some researchers are also investigating its potential for managing metabolic issues, though this is not a primary FDA-recognized use. Always consult a healthcare provider before using it for any medical condition.
The most common side effects are localized to the skin when the extract is used topically. Patients frequently report mild burning, stinging, or itching immediately after application. Some individuals may also experience skin redness or a dry, tight sensation in the treated area. If taken orally, common side effects include mild stomach upset, such as nausea or cramping. These effects are usually temporary and do not require discontinuation of the treatment unless they become severe.
It is generally advised to avoid or significantly limit alcohol consumption while using Mahonia Aquifolium Root Bark. Alcohol can worsen inflammatory skin conditions like psoriasis, potentially neutralizing the benefits of the medication. Additionally, because both alcohol and the alkaloids in the root bark are processed by the liver, combining them can increase the workload on your liver. There is also a risk of increased gastrointestinal irritation when oral extracts are taken with alcohol. Discuss your alcohol intake with your doctor to ensure safety.
No, Mahonia Aquifolium Root Bark is considered unsafe for use during pregnancy. The active alkaloid, berberine, can cross the placenta and may cause harm to the developing fetus, including a risk of brain damage known as kernicterus. It may also act as a uterine stimulant, which could potentially lead to miscarriage or early labor. Healthcare providers strongly recommend avoiding all forms of this extract—oral and topical—while pregnant. Always inform your doctor if you are pregnant or planning to become pregnant before starting this medication.
The timeframe for seeing results depends on the condition being treated and the form of the medication used. For topical treatment of psoriasis, patients typically begin to see improvement in skin redness and scaling within 4 to 8 weeks of consistent use. Maximum therapeutic benefits are often reached after 12 weeks of application. For allergy desensitization, the process is much slower, often taking several months of 'build-up' injections before significant relief is felt. If you do not see improvement after 8 weeks of topical use, consult your dermatologist.
While Mahonia Aquifolium Root Bark does not cause a physical dependence or a traditional withdrawal syndrome, stopping it suddenly may cause issues. For skin conditions like psoriasis, abruptly halting topical application can lead to a 'rebound effect' where symptoms return or temporarily worsen. It is generally better to gradually reduce the frequency of application as your skin clears. If you are receiving allergy shots, stopping suddenly will halt the desensitization process and your allergies may return. Always consult your healthcare provider before changing your treatment regimen.
If you miss a dose of Mahonia Aquifolium Root Bark, apply it or take it as soon as you remember. However, if it is nearly time for your next scheduled dose, you should skip the missed one and continue with your regular timing. Do not apply extra cream or take a double oral dose to make up for the one you missed, as this can increase the risk of side effects. Consistency is key for the effectiveness of this treatment, especially for skin conditions. If you miss multiple doses, contact your healthcare provider for guidance.
There is currently no clinical evidence to suggest that Mahonia Aquifolium Root Bark causes weight gain. In fact, some research into its primary alkaloid, berberine, suggests it may have a minor beneficial effect on metabolism and weight management by activating the AMPK pathway. However, it is not approved as a weight-loss medication. If you experience unexpected weight changes while using this product, it is likely due to other factors or underlying health conditions. You should discuss any significant weight changes with your healthcare provider.
Mahonia Aquifolium Root Bark has several significant drug interactions that require caution. It can increase the levels of medications like cyclosporine and certain statins by inhibiting the CYP3A4 enzyme, which could lead to toxicity. It may also interfere with blood pressure medications and blood sugar-lowering drugs for diabetes. Because of these risks, it is essential to provide your doctor with a full list of all prescription drugs, over-the-counter medicines, and herbal supplements you are currently taking. Never start a new medication while using Mahonia without medical clearance.
Mahonia Aquifolium Root Bark is a botanical extract rather than a synthetic drug, so the concept of 'generic' vs. 'brand name' is slightly different. It is available from various manufacturers as a non-standardized extract, homeopathic dilution, or herbal supplement. While there are no 'generic versions' of a specific patented molecule, you will find many different brands offering Oregon Grape root bark products. It is important to choose a reputable manufacturer to ensure quality and purity, as botanical products are not regulated as strictly as prescription drugs.
> Warning: Stop taking Mahonia Aquifolium Root Bark and call your doctor immediately if you experience any of these.
No FDA black box warnings have been issued specifically for Mahonia Aquifolium Root Bark. However, as a Non-Standardized Plant Allergenic Extract, it carries inherent risks of severe allergic reactions during administration. It should only be administered in a clinical setting equipped with emergency resuscitation equipment (e.g., epinephrine, oxygen) when used as an injectable extract.
Report any unusual symptoms to your healthcare provider.
If you are using Mahonia Aquifolium Root Bark long-term or in high oral doses, your healthcare provider may require:
Generally, Mahonia Aquifolium Root Bark does not cause sedation. However, if you experience dizziness or palpitations as a side effect of its adrenergic properties, do not drive or operate heavy machinery until you know how the medication affects you.
Alcohol should be avoided or minimized. Alcohol can exacerbate skin conditions like psoriasis and may increase the risk of gastrointestinal irritation when combined with oral root bark extracts. Furthermore, both alcohol and Mahonia alkaloids are processed by the liver, potentially increasing hepatic strain.
There is no known withdrawal syndrome associated with Mahonia Aquifolium Root Bark. However, for conditions like psoriasis, 'rebound' (a sudden worsening of symptoms) can occur if topical treatment is stopped abruptly. It is often recommended to taper the frequency of application rather than stopping suddenly.
> Important: Discuss all your medical conditions with your healthcare provider before starting Mahonia Aquifolium Root Bark.
For each major interaction, the mechanism is usually related to CYP3A4 inhibition or P-glycoprotein modulation. The clinical consequence is typically an increase in the toxicity of the co-administered drug or an unpredictable shift in autonomic tone. Management strategies involve either avoiding the combination or performing frequent therapeutic drug monitoring (TDM).
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Conditions requiring careful risk-benefit analysis include:
Patients who are allergic to the following may also react to Mahonia Aquifolium Root Bark:
These plants all share similar alkaloid profiles, particularly the presence of berberine, which can be the primary sensitizing agent.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Mahonia Aquifolium Root Bark.
Clinical studies have not identified specific differences in response between the elderly and younger patients. However, geriatric patients are more likely to have decreased renal or hepatic function and are often on multiple medications (polypharmacy). The risk of drug-drug interactions, particularly with anticoagulants and antihypertensives, is significantly higher in this population. Monitoring for orthostatic hypotension (dizziness upon standing) is recommended due to potential adrenergic effects.
In patients with impaired kidney function, the clearance of alkaloid metabolites may be reduced. While no specific GFR-based dosing exists, patients with a GFR < 30 mL/min should be monitored for signs of systemic toxicity, such as gastrointestinal distress or cardiac palpitations.
Mahonia Aquifolium is heavily metabolized by the liver. In patients with Child-Pugh Class B or C impairment, the half-life of its active alkaloids may be significantly prolonged. Oral use is generally not recommended in these patients. If used, LFTs should be performed at baseline and every 4 weeks thereafter.
> Important: Special populations require individualized medical assessment.
| Parameter | Value |
|---|---|
| Bioavailability | < 5% (Oral) |
| Protein Binding | ~85-90% (Albumin) |
| Half-life | 3 - 6 hours |
| Tmax | 1.5 - 2.5 hours (Oral) |
| Metabolism | Hepatic (CYP3A4, 2D6) |
| Excretion | Fecal (major), Renal (minor) |
Mahonia Aquifolium Root Bark is categorized as a Non-Standardized Plant Allergenic Extract. It is related to other isoquinoline alkaloid-containing plants like Berberis vulgaris and Hydrastis canadensis. Unlike standardized pharmaceuticals, its exact composition can vary based on the harvest season and extraction method.